INTRODUCTION
Lysosomal integral membrane glycoproteins (lysosomal glycoproteins [lgps] , lysosomal integral membrane proteins [LIMPs] , lysosome-associated membrane proteins [LAMPs] ) have short, 10 -20 amino acid, cytosolic tails containing tyrosine-based or di-leucine-based motifs that are known, or thought, to determine their lysosomal targeting . The tyrosine-based signals are of the form YXXØ where X is any amino acid and Ø is a bulky hydrophobic amino acid, and are clearly related to internalization signals of the same type, which interact with the 2 subunit of the AP-2 adaptor found in clathrin-coated pits at the cell surface . Lysosomal targeting YXXØ motifs are often located at the carboxy terminus of short cytosolic tails preceded by a glycine. Their effectiveness may be modified by spacing relative to the membrane bilayer (Rohrer et al., 1996) , the identity of the carboxyterminal amino acid (Gough and Fambrough, 1997; Gough et al., 1999) , or proteolytic modification (Guarnieri et al., 1993; Akasaki et al., 1995) . There is evidence that the lumenal (Reaves et al., 1998) and transmembrane domains (Wimer-Mackin and Granger, 1996) of some lgps also contain targeting information.
Newly synthesized lgps with GYXXØ motifs in their carboxyterminal cytosolic tails take both direct and indirect (via the plasma membrane) traffic routes from the trans-Golgi network (TGN) to lysosomes. The evidence for individual lgps taking mainly one or other of these routes has come from kinetic studies of delivery and from the endocytic uptake of anti-lgp antibodies or surface-labeled lgps from the plasma membrane. Thus, the type I integral membrane proteins LAMP-1 and LAMP-2, which between them account for Ͼ50% of the lysosomal content of lgps (Andrejewski et al., 1999) , are delivered from the TGN with half-times of 30 -90 min, mainly via an intracellular route (Barriocanal et al., 1986; D'Souza and August, 1986; Green et al., 1987; Carlsson and Fukuda, 1992; Akasaki et al., 1995 Akasaki et al., , 1996 . In contrast, lysosomal acid phosphatase, also a type I mem-brane protein with a cytosolic tail GYXXØ motif, is delivered with a half-time of 5-7 h, mainly via the cell surface (Braun et al., 1989) .
The nature of the vesicular carriers used by lgps on the direct route from the TGN to late endocytic compartments is a matter of some dispute. Evidence that the intracellular route taken by some lgps from the TGN to lysosomes involves adaptor protein (AP)-1-associated clathrin-coated vesicles has mainly come from data showing that in vitro the LAMP-1 cytosolic domain interacts with both purified AP-1 and AP-2 and that in vivo, a small fraction, ϳ3%, of intracellular LAMP-1 is present with mannose 6-phosphate receptors (MPRs) in AP-1-associated clathrin-coated vesicles budding from the TGN (Honing et al., 1996) . However, more recent studies showed first, that LAMP-1 and LAMP-2 were mostly in separate TGN-derived vesicles from those containing MPR and AP-1 (Karlsson and Carlsson, 1998) , and second, that in 1A-deficient cells no change in steady-state distribution or missorting to the cell surface of LAMP-1 occurred, in contrast to the altered MPR distribution (Meyer et al., 2000) . The recently discovered clathrin adaptors known as Golgi-localized, ␥-ear containing, ARF-binding proteins which are the best candidates for signal-mediated sorting of MPRs at the TGN, appear to play no role in LAMP-1 delivery to lysosomes (Puertollano et al., 2001) . Over the past 5 yr considerable, but mostly indirect, evidence has been obtained to suggest that AP-3 plays a role in the targeting of lgps to lysosomes and lysosome-like organelles (reviewed in Hirst and Robinson, 1998; Gu and Gruenberg, 1999; Luzio et al., 2000; Huizing et al., 2001; Mullins and Bonifacino, 2001 ). In yeast it has been established that two different trafficking routes from the late Golgi to the lysosome exist, which are followed by different newly synthesized proteins, and one of which is AP-3 dependent (Cowles et al., 1997; Piper et al., 1997; Stepp et al., 1997) .
To obtain further information about the targeting of lgps to lysosomes and the role of AP-3, we have studied lysosomal targeting of CD63 (LIMP-I, LAMP-3), a member of the tetraspanin family of integral membrane proteins with four predicted transmembrane domains (Metzelaar et al., 1991; Maecker et al., 1997) . CD63 was first described as an antigen present on the surface of activated blood platelets after transfer from dense granules (Modderman, 1989) . It was later shown to colocalize with other lgps in a variety of cell types (Metzelaar et al., 1991) , consistent with its predicted 10-amino acid, cytosolic, carboxyterminal tail ending in the sequence GYEVM. More recently, it has been shown to be enriched on intralumenal vesicles in late endosomes/lysosomes (Escola et al., 1998; Kobayashi et al., 2000; Piper and Luzio, 2001) . The kinetics of delivery of newly synthesized CD63 from the TGN to lysosomes has shown a half-time of 2 h, implying that an intracellular delivery route is likely to be important (Barriocanal et al., 1986) .
MATERIALS AND METHODS

Reagents
Unless otherwise stated reagents were purchased from Sigma Chemical (Poole, Dorset, United Kingdom). Wortmannin was purchased from Calbiochem (Nottingham, United Kingdom) and was aliquoted at Ϫ20°C as a 1 mM stock in dimethyl sulfoxide. Restriction endonucleases, shrimp alkaline phosphatase, polynucleotide kinase, and DNA polymerases were purchased from New England Biolabs (Hitchin, United Kingdom). Rat CD63 cDNA in pUEX was a gift from Drs. C. Wasmeier and J.C. Hutton (Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, CO). A human cDNA library from Raji cells (QUICK-Clone cDNA; CLON-TECH, Palo Alto, CA) was used as a source of human CD63 cDNA, which was recovered by standard polymerase chain reaction (PCR) techniques. Human CD8 ␣-chain cDNA in the vector S85 was a gift from Dr. S. Munro (MRC Laboratory of Molecular Biology, Cambridge, United Kingdom), contained an AflII site at the end of the transmembrane region, and was cloned into ⌬pMEP4 (Girotti and Banting, 1996) as previously described (Ihrke et al., 2000) . Oligonucleotides were from R&D Systems (Abingdon, United Kingdom) and Genosys (Cambridge, United Kingdom).
The species-specific mouse monoclonal antibody (mAb) to rat CD63, designated AD1 (Kitani et al., 1991; Nishikata et al., 1992) , was a gift from Dr. R.P. Siraganian (National Institutes of Health, Bethesda, MD). The species-specific mouse mAb to human CD63, designated CLB-gran/12, was purchased from Biodesign International (Kennebunk, ME). Fluorescein isothiocyanate-labeled CLBgran/12 antibody used for fluorescence-activated cell sorting (FACS) analysis was purchased from Immunotech (Marseille, France). Rabbit polyclonal antisera to rat LAMP-2 (lgp110), rat ciMPR, rat TGN38, and mouse mAb to rat TGN38 were as described (Horn and Banting, 1994; Reaves et al., 1996) . Rabbit polyclonal anti-rat cathepsin D was a gift from Dr. H.W. Davidson (University of Cambridge, Cambridge, United Kingdom). Rabbit polyclonal anti-␥ adaptin and anti-␤NAP (␤3B) were gifts from Dr. M.S. Robinson (University of Cambridge). Rat monoclonal antihuman CD8␣ (Bindon et al., 1989 ) was a gift from Dr. G. Hale (University of Oxford, Oxford, United Kingdom). Rabbit polyclonal anti-human cathepsin D was purchased from DAKO (Ely, Cambridgeshire, United Kingdom). The rat mAb to mouse LAMP-1 (1D4B) developed by T. August was from the Developmental Studies Hybridoma Bank (Department of Biological Sciences, University of Iowa, Iowa City, IA). Fluorescein isothiocyanate-labeled goat anti-mouse IgG, Texas Red-labeled goat anti-mouse IgG, and Texas Red-labeled donkey anti-rabbit IgG were obtained from Amersham (Little Chalfont, Buckinghamshire, United Kingdom). Texas Red-X-labeled goat anti-rat IgG was from Molecular Probes (Eugene, OR).
Mocha, pearl, and stably transfected mocha cells expressing the ␦ subunit of AP-3 were as described (Peden et al., 2002) and were gifts from Dr. M.S. Robinson (University of Cambridge).
Recombinant DNA Procedures
Standard molecular biology procedures (Sambrook et al., 1989) , with the variations previously described (Reaves et al., 1998) , were performed unless otherwise stated. Human and rat CD63 molecules containing single amino acid replacements in the cytosolic tail were prepared by mutating cDNA with standard PCR techniques. Details of all primers used are available from the corresponding author on request.
To construct a chimera containing the lumenal and transmembrane domains of CD8 and the cytosolic tail of CD63(CD8-CD63), a corresponding piece of CD63 cDNA was amplified by PCR, introducing an AflII site at the final transmembrane/cytosolic tail boundary. The resulting expressed amino acid sequence after joining the AflII-digested CD8 cDNA and CD63PCR product was . . . TLYCK-RLKSIRSGYEVM, with the underlined 10 residues from CD63 and all other residues from CD8.
The chimera in which the carboxyterminal cytosolic tail of CD63 was replaced by that of TGN38 (CD63-TGN38) was constructed in the same way as the lgp120-TGN38 chimeras described previously (Reaves et al., 1998) . A fragment of human CD63 cDNA encoding the entire molecule except the carboxyterminal cytosolic tail, and containing a SalI site at the 3Ј end, was generated by PCR. A piece of TGN38 cDNA encoding the cytosolic tail was amplified by PCR B.A. Rous et al. from ⌬pMEP-LTT, one of the lgp120-TGN38 chimeras, so that it contained a SalI site at the transmembrane/cytosolic tail boundary. The resulting expressed amino acid sequence after joining the SalIdigested CD63 cDNA and TGN38 PCR product was . . . AC-CLVDHNKRKIIAFALEGKRSKVTRRPKASDYQRLNLKL, with the underlined 34 residues from TGN38, the preceding D from the SalI cloning site and all other residues from CD63.
All cDNA constructs prepared as described above were ligated into the multiple cloning site in the mammalian expression vector ⌬pMEP4 (Girotti and Banting, 1996) and their DNA sequences confirmed by dideoxy chain termination sequencing, with the service provided by the Department of Genetics (University of Cambridge).
Cell Culture and Transfection
Normal rat kidney (NRK), COS-7, NIH-3T3, pearl, and mocha cells were grown in tissue culture flasks or on glass coverslips as previously described for NRK cells (Reaves et al., 1998) . COS-7 cells were transfected by electroporation (Reaves et al., 1998) and mocha cells with calcium phosphate coprecipitation (Robinson, 1990) , as previously described. NRK cells were transfected using Transfectam reagent (Promega, Southampton, United Kingdom) or FugGENE 6 (Roche Diagnostics, Lewes, East Sussex, United Kingdom), NIH-3T3 fibroblasts with LipofectAMINE (Invitrogen, Carlsbad, CA), and pearl cells with Superfect (QIAGEN, Chatsworth, CA), according to the manufacturers' instructions. Selection and growth of stable cell lines and stimulation of protein expression in cells transfected with ⌬pMEP4 constructs were as previously described (Reaves et al., 1998) . Expression levels of mutant human CD63 in stably transfected NRK cells used for immunofluorescence and fluorescenceactivated cell sorting (FACS) analysis were shown by quantitative immunoblotting to be between 80 and 135% of the expression level of wild-type human CD63 in the stably transfected NRK cells.
Immunofluorescence Microscopy
Indirect immunofluorescence microscopy and antibody uptake experiments were carried out as previously described (Reaves et al., 1998) .
FACS Analysis
Approximately 10 7 stable transfected NRK cells growing in a 150-cm 2 tissue culture flask were removed from the culture dish and treated essentially as described by Dell'Angelica et al. (1999) , except that cells were fixed with 4% paraformaldehyde in phosphatebuffered saline (PBS) for 10 min at 20°C and half was permeabilized with 0.1% Triton X-100 in PBS/1% bovine serum albumin. Intact or permeabilized cells were incubated for 45 min on ice with fluorescein-conjugated CLB-gran12 antibody to human CD63 (10 ng/ml) in 100 l PBS/1% bovine serum albumin and subsequently analyzed on a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ). Positively fluorescent cells were identified as those with fluorescence intensities Ͼ97.5% of nontransfected cells. The ratio of positive cells in intact and permeabilized preparations was used to calculate the proportion of intracellular wild-type or mutant human CD63 in the transfected NRK cells. FACS data from each stably transfected cell line are presented relative to the amount of intracellular CD63 in the cell line expressing the wild-type human protein. This was 36% of total expressed CD63, i.e., at a level similar to that of a transfected chimeric lgp in a previous study where it was shown that lgp trafficking machinery was not saturated (Gough and Fambrough, 1997) .
Yeast Two-Hybrid System
The two-hybrid system used to investigate the interactions between AP subunits and wild type, and mutated cytosolic domains of CD63 was as previously described (Stephens and Banting, 1998; Hirst et al., 1999) . Constructs encoding subunits in the two-hybrid transcriptional activation domain vector pVP16 were as described (Stephens and Banting, 1998) . Wild-type (KSIRSGYEVM) and mutant versions of the carboxyterminal cytosolic tail of CD63 were amplified by PCR and subcloned into the two-hybrid DNA-binding domain vector pBTM116. The yeast strain L40, maintained as previously described (Stephens and Banting, 1998) , was cotransformed with two plasmids by using a polyethylene glycol-lithium acetate procedure and plated onto selective medium lacking leucine and tryptophan to select for colonies containing both plasmids. After 3-4 d, colonies were incubated in liquid cultures to perform quantitative growth assays. Liquid cultures were set up by inoculating 0.15 OD 600 units of cells into 2 ml of selective medium lacking leucine, trytophan, and histidine and were assayed for growth after 0 -180 h of incubation at 30°C by measurement of OD 600 . Each time point was assayed in triplicate. Quantitative ␤-galactosidase assays and determination of inhibition of cell growth with 3-amino-1,2,4-triazole (3-AT) were as previously described (Stephens and Banting, 1998) . Growth curves were calculated using SigmaPlot 4.01 (Jandel Scientific, San Rafael, CA).
RESULTS
When cDNAs encoding human CD63, and a chimera of CD8 and the carboxyterminal cytosolic tail of CD63 (CD8-CD63) were transfected into NRK cells, the steady-state localization of expressed protein was essentially indistinguishable from that of endogenous LAMP-2 by fluorescence microscopy ( Figure 1, A-D) . CD8-CD63 was also observed to colocalize with endogenous rat CD63 (our unpublished data). As a control for CD8-CD63, the localization of expressed CD8 was examined in transfected NRK cells and found to be at the cell surface as expected (Figure 1, E and F) . The intracellular localization of CD8-CD63 indicated that the carboxyterminal cytosolic tail of CD63 is sufficient to target the "neutral" plasma membrane reporter protein CD8 to lysosomes. To test whether targeting information is also present in lumenal or transmembrane domains, we examined the steady-state localization of CD63-TGN38, a chimera in which the carboxyterminal cytosolic tail of TGN38 replaced that of CD63. This TGN38 tail has been shown to localize a variety of chimeras containing the transmembrane and extracellular domains of neutral plasma membrane proteins to the TGN (Reaves et al., 1998) . CD63-TGN38 expressed in transfected NRK cells colocalized with LAMP-2 (Figure 1, G and H) and not with TGN38 (our unpublished data), suggesting that as for LAMP-1 and LAMP-2 (Reaves et al., 1998) , the lumenal and/or transmembrane domains of CD63 also contain lysosomal targeting information.
To examine the role of the GYXXØ (GYEVM) motif of the carboxyterminal cytosolic tail of CD63 in lysosomal targeting of this protein we carried out alanine scanning mutagenesis of this motif in human CD63. Stably transfected NRK cells expressing the mutant proteins were analyzed by immunofluorescence microscopy to determine the steady-state localization of the different mutated proteins (Figure 2 ). This showed that mutation of the G, Y, E, or M to A resulted in increased expression on the cell surface, but mutation of V to A had no effect (compare Figure 2 , A-J, with wild-type in Figure 1A ). Overall, the microscopy showed the order of greatest expression on the cell surface of the mutants was GAEVM Ͼ GYEVA Ͼ GYAVM Ͼ AYEVM Ͼ wild-type (GYEVM) ϭ GYEAM. The conservative mutation of Y to F (GFEVM) resulted in increased surface localization of the AP-3 and CD63 Targeting Vol. 13, March 2002 mutated CD63 (Figure 2 , K and L). The effect of mutating E to A (GYAVM) was particularly unexpected in the context of a GYXXØ motif and was therefore further analyzed by FACS analysis, which showed that it resulted in a reduced proportion of the protein being expressed at an intracellular location(s). In contrast, FACS analysis showed that the conservative mutation of M to I (GYEVI) increased intracellular localization (Figure 3 ), although this was not easily detected by immunofluorescence microscopy ( Figure 2, M and N) . The data obtained on the localization of alanine scan mutants of human CD63 expressed in NRK cells are not species specific because comparable data were obtained by immunofluorescence microscopy of equivalent alanine scan mutants of rat CD63 expressed in transfected COS-7 cells (our unpublished data). The sequences of the carboxyterminal cytosolic tails of rat and human wild-type CD63 are identical.
The observation that mutation of E to A within the GYEVM motif resulted in greater cell surface localization of CD63 was initially surprising given the consensus sequence for the motif as GYXXØ. However, data obtained by screening the interaction of adaptor subunits with a combinatorial XXXYXXØ library, by using the yeast two-hybrid system, suggested that an E at the Y ϩ 1 position results in a YXXØ motif with preferential binding to 3 (Ohno et al., 1998) . We therefore decided to investigate the interaction of wild-type and mutant carboxyterminal cytosolic tails of CD63 with subunits in the yeast two-hybrid system. The subunits were cloned into the two-hybrid transcriptional activation domain vector pVP16, and wild-type and mutated carboxyterminal cytosolic tails of CD63 were cloned into the two-hybrid DNA-binding domain vector pBTM116. Pairs of constructs were then transformed into yeast cells, and interaction between the cytosolic tails and subunits assayed by the ability of cells coexpressing them 1) to grow on agar or in liquid medium lacking histidine; 2) to induce ␤-galactosidase expression; or, for strong interactors, 3) to grow in the presence of 3-AT, a competitive inhibitor of histidine biosynthesis. By using this two-hybrid system and measuring interaction by growth in medium lacking histidine, it has previously been shown that the wild-type carboxyterminal cytosolic tail of CD63, containing GYEVM, interacts most strongly with 3A, weakly with 2 and 4, and not at all with 1 (Hirst et al., 1999) . There was an equally strong interaction with the brain-specific isoform 3B (our unpublished data). The interaction of mutated CD63 tails with 3A and 2 was shown by growth on agar lacking histidine (Figure 4) . Clearly, the tails containing Y-to-A and M-to-A mutations interacted very poorly with 3A because no growth was observed. Interactions with 2 occurred only with three constructs (GYEVM, GYAVM, and GYEAM) and were all weak, resulting in poor growth on the agar (Figure 4) . To characterize the relative strengths of interaction of the mutated tails with 3A in more detail, growth of cotransformed yeast was measured in medium lacking histidine Ͼ180 h ( Figure 5, A and B) . The strengths of interaction of the weakly interacting mutated tails with 3A were easily distinguished by this method. The relative strengths of interaction of the strongly interacting wild-type and mutated tails were distinguished better by plotting dose-response curves of 3-AT inhibition of growth of cotransformed yeast in medium lacking histidine ( Figure 5C ) or measurement of ␤-galactosidase activity after growth in medium containing histidine ( Figure 5D ). Taking these data together, the strength of interaction of wild-type and mutated tails of CD63 with 3A was determined to be wildtype (GYEVM) ϭ GYEAM Ͼ AYEVM Ͼ GYAVM Ͼ Ͼ GYEVA Ͼ Ͼ GAEVM. This order is the exact reverse of that describing cell surface expression of CD63 molecules containing these mutated tails in transfected NRK cells (Figures  2 and 3) .
In the yeast two-hybrid experiments we also examined the strength of interaction of 3A with a mutated CD63 tail in which M was mutated to I (GYEVI). This construct was chosen because the data from the combinatorial XXXYXXØ library presented by Ohno et al. (1998) showed that for interaction with 3A, I is favored in the Y ϩ 3 position. We found that the mutated CD63 tail in which M was mutated to I showed the strongest interaction with 3A of any tail sequence we examined ( Figure 5 , A, C, and D) and CD63 containing this mutation had the lowest surface expression in transfected NRK cells ( Figures 2K and 3) . These data were not due to the creation of a dileucine-type motif of the form VI because CD63 with the mutated tail GAEVI was expressed entirely on the cell surface (our unpublished data). We also observed in the yeast two-hybrid system that the mutated CD63 tail in which M was mutated to I showed no interaction with 2 (Figure 4 ). This implied that any CD63 containing this mutation delivered to the cell surface in transfected cells would be poorly internalized by clathrinmediated endocytosis. To test this, we investigated anti- human CD63 antibody uptake in stable lines of NRK cells transfected with wild-type (GYEVM) and mutated (GYEVI) CD63. Less intracellular accumulation of antibody was observed in cells expressing the mutated (GYEVI) CD63, consistent with inefficient clathrin-mediated uptake (Figure 6) .
The experiments described above, together with published data on the kinetics of delivery of wild-type CD63 from TGN to lysosomes, strongly suggest that the wild-type protein traffics to lysosomes from the TGN by an intracellular AP-3-dependent route, but that any CD63 reaching the cell surface is internalized by AP-2-dependent clathrin-mediated endocytosis and delivered by the endocytic pathway to lysosomes. In contrast, mutated (GYEVI) CD63 should only reach lysosomes by an intracellular AP-3-dependent route and any delivered to the cell surface should not be efficiently internalized and delivered by endocytosis. To test this hypothesis we expressed human wild-type and mutated (GYEVI) CD63 in cells from pearl and mocha mice and, using immunofluorescence microscopy, examined the steady-state distribution of the recombinant expressed protein. As a control we also transfected wild-type mouse NIH-3T3 fibroblasts. Consistent with our hypothesis, mutated (GYEVI) CD63 was observed almost exclusively on the surface of pearl and mocha cells but colocalized with an endogenous lgp (LAMP-1) in NIH-3T3 fibroblasts (Figures 7 and 8 ). In contrast, wild-type (GYEVM) CD63 colocalized with endogenous LAMP-1 in transfected pearl and mocha cells (Figures 7  and 8 ). Similar results were obtained from both transiently transfected cells and stable transfected cell lines. To test our hypothesis further, two additional experiments were carried out. In the first, we transfected mocha cells that had been rescued by expression of the ␦ subunit of AP-3 with mutated (GYEVI) CD63. In the rescued cells expressing the ␦ subunit of AP-3 at a concentration sufficient for detection by immunofluorescence, a significant proportion of the expressed mutated (GYEVI) CD63 colocalized with intracellular, endogenous LAMP-1 (Figure 9 ). In the second experiment, we further transfected a stable line of pearl cells expressing mutated (GYEVI) CD63 with a cDNA construct encoding the ␤3B subunit of AP-3. Some intracellular localization of mu- Figure 4 . Interaction of the cytosolic domains of CD63 and mutated CD63 with 2 and 3A in the yeast two-hybrid system. Yeast cells were transformed with bait constructs (LexA fusion) containing the C-terminal cytosolic domains of CD63, and the mutant forms AYEVM, GAEVM, GYAVM, GYEVA, GYAVM, GYEAM, GYEVA, and GYEVI and a prey construct (either VP16-2, VP16-3A). Transformed yeast were grown on agar plates in the absence of histidine for 3 d (3A) or 10 d (2). All transformed yeast grew in the presence of histidine and no transformed yeast containing "empty" VP16 grew in the absence of histidine. tated (GYEVI) CD63 was observed in cells expressing ␤3B (our unpublished data; ␤3B was used in this experiment because of the lack of antibodies to ␤3A for immunofluorescence).
The data presented above are consistent with the mutated (GYEVI) CD63 absolutely requiring functional AP-3 for targeting to lysosomes and provided us with a unique reporter protein for this pathway. As discussed in INTRODUCTION it has been reported that AP-3 is associated with endosomes as well as with the TGN (Simpson et al., 1996; Dell'Angelica et al., 1998) . Because chloroquine treatment of cells causes swelling of endocytic compartments and blocks traffic through the early endosome (Reaves et al., 1998) we predicted that if mutated (GYEVI) CD63 was trafficking via this compartment it should be trapped there after chloroquine treatment along with TGN38, which normally cycles between the TGN and cell surface/early endosome (Chapman and Munro, 1994; Reaves and Banting, 1994; Banting et al., 1998) . However, no mutated (GYEVI) CD63 was observed in the same structures as TGN38 in chloroquine-treated, transfected NRK cells (Figure 10, A and B) . In contrast, when CD63-TGN38 -expressing NRK cells were treated with chloroquine, CD63-TGN38 was observed in the same swollen structures as endogenous TGN38 (Figure 10 , C and D) consistent with this molecule trafficking via an early endosome, i.e., by a different route to the AP-3-dependent route used by mutated (GYEVI) CD63. Other swollen structures depleted of TGN38 also contained CD63-TGN38, consistent with them being late endosomes and lysosomes containing CD63-TGN38 molecules that had arrived before the chloroquine was added. When NRK cells expressing wild-type human CD63 were incubated with chloroquine, this protein was mainly in separate structures to TGN38, although some colocalization was observed that presumably represents the small proportion of wild-type CD63 that traffics via the early endosome ( Figure 10, E and F) . These data taken together suggest that the AP-3-dependent pathway of membrane traffic from the TGN to lysosomes does not involve traffic via the early endosomal compartment in which TGN38 accumulates after chloroquine treatment.
DISCUSSION
The increased surface expression of CD63 in which G, Y, or M was mutated to A confirmed the importance of the GYEVM sequence in the localization of this protein, as is the case for the GYXXØ motif in the carboxyterminal cytoplasmic tail of other lgps, including lysosomal acid phosphatase (Peters et al., 1990; Lehmann et al., 1992) , LAMP-1 (Williams and Fukuda, 1990; Harter and Mellman, 1992; Guarnieri et al., 1993) , and LAMP-2 isoforms (Gough and Fambrough, 1997) .
The observation that mutating E to A in the carboxyterminal cytosolic tail of CD63 produced a mutant protein that was more expressed at the cell surface than wild-type protein was unexpected because mutations at the Y ϩ 1 position of the GYXXØ motif have been shown to have no effect on lysosomal targeting of LAMP-1 (Guarnieri et al., 1993; Honing and Hunziker, 1995; Rohrer et al., 1996) . It stimulated our use of the yeast two-hybrid system to investigate the interaction of wild-type and mutated cytosolic tails of CD63 with adaptor medium chain () subunits. From their screen of the interactions with subunits of a combinatorial peptide li- brary, Ohno et al. (1998) observed a preference for E at the Y ϩ 1 position of a YXXØ motif for interaction with 3A and 3B. They pointed out that this was "noteworthy because it is a characteristic of proteins targeted to lysosomes or lysosome-related organelles, such as . . . CD63." Their data also showed a preference for G rather than A at the Y Ϫ 1 position and I rather than M at the Y ϩ 3 position for interaction with 3A. Our own yeast two-hybrid data are consistent with the data from Ohno et al. (1998) , but in our case within the context of the actual cytosolic tail of an lgp. More importantly, we have shown for the first time that the order of cell surface versus lysosomal distribution of GYXXØ mutants of an lgp is accurately predicted by interactions with 3A in the yeast two-hybrid system. Two other complete cytosolic tails containing YXXØ motifs have previously been shown to be capable of interacting with adaptor chains in the yeast two-hybrid system: those of TGN38 and LAMP-1 (Ohno et al., 1995; Stephens et al., 1997; Stephens and Banting, 1998) . In both these cases, and for the tail of CD63, interaction is dependent on the Y and the Ø in the YXXØ motif.
In our yeast two-hybrid experiments we observed that a mutated CD63 tail in which M was mutated to I (GYEVI) did not interact with 2, despite showing the strongest interaction with 3A of all the mutated tails examined. Consistent with this observation, examination of the combinatorial XXXYXXØ peptide library screen of Ohno et al. (1998) reveals that for interaction with 2, I is more disfavored than M at the Y ϩ 3 position. The availability of a mutated CD63 that interacts strongly with 3A but not with 2 allowed us to test a number of predictions about its behavior, and the role of the AP-3-dependent trafficking pathway, when it was expressed in cultured cells. In particular, we predicted and showed that, in cells lacking functional AP-3, the GYEVI mutant of CD63 was unable to reach lysosomes because it was denied the AP-3-dependent intracellular route and could not be internalized from the cell surface. This route was recovered and the GYEVI mutant correctly delivered to lysosomes in mocha cells, which had been rescued by expression of the ␦ subunit of AP-3. In contrast, wild-type CD63 was still delivered to lysosomes in transfected pearl and mocha cells, consistent with the ability to be internalized efficiently from the cell surface. Our experiments have identified the first lgp, the GYEVI mutant of CD63, to be grossly mislocalized in AP-3-deficient cells. They are also consistent with previous experiments where endogenous lgps were observed to traffic to lysosomes via the cell surface in AP-3-deficient cells or in cells in which functional AP-3 concentrations were reduced by transfecting with antisense oligonucleotides to 3A (Le Borgne et al., 1998) .
The intracellular site of action of AP-3 in lysosomal targeting has not been well defined. It is unlikely that AP-3 acts at the plasma membrane because it would be difficult to reconcile such a site of action with the observation that increased quantities of lgps traffic via the cell surface in cells deficient in AP-3 (Le Borgne et al., 1998; Dell'Angelica et al., 1999) . Moreover, it has been localized by microscopy at or close to the TGN (Simpson et al., 1996) and on endosomes (Dell'Angelica et al., 1998) . It thus seems likely that AP-3 functions to traffic between the TGN and lysosomes on a route equivalent to the AP-3-mediated direct trafficking pathway from the Golgi complex to the vacuole proposed in yeast and used by alkaline phosphatase but not carboxypeptidase Y (Cowles et al., 1997) . In the present experiments we studied the effects of chloroquine on the distribution of transfected wild-type CD63 and a chimera with the cytoplasmic tail of TGN38 to provide further insights into the intracellular site of action of AP-3. Previous work has shown that endosomal acidification is important for transport from endosomal compartments to both lysosomes and the TGN (Chapman and Munro, 1994; Reaves and Banting, 1994; Van Weert et al., 1995) , such that when the pH of endosomes is raised using either a proton pump inhibitor (e.g., bafilomycin A1) or a membrane-permeant weak base (e.g., chloroquine), membrane proteins, including TGN38, furin, LAMP-1, and lysosomal acid phosphatase become trapped in early endosomal compartments (Braun et al., 1989; Chapman and Munro, 1994; Reaves and Banting 1994; Reaves et al., 1998) . In addition, delivery of endocytosed horseradish peroxidase from endosomes to lysosomes is impaired (Van Weert et al., 1995) . Thus, in the present study, chloroquine was used to inhibit traffic through early endosomal compartments and to see whether wild-type CD63 or the GYEVI mutant were trapped in early endosomes en route to the lysosomes. Some wild-type CD63 was trapped in early endosomes, suggesting that a proportion traffics through this compartment. In contrast, none of the GYEVI mutant was found in early endosomes, consistent with it trafficking from the TGN to lysosomes by an AP-3-dependent intracellular route that does not involve passage through early endosomes. As a control, we studied the CD63-TGN38 chimera that has a TGN38 cytosolic tail that interacts strongly with 2, weakly with 1, and barely detectibly with 3 in the yeast two-hybrid system (Ohno et al., 1995; Stephens and Banting, 1998 ; our unpublished data). CD63-TGN38 was found in endosomal structures when chloroquine was added to the cells, suggesting that, as predicted, it does indeed traffic through early endosomes.
Why does wild-type CD63 have a GYEVM motif rather than a GYEVI motif if the latter is more efficient for AP-3-dependent delivery to the lysosome? One possible explanation is that because of the poor interaction of GYEVI with 2 any CD63 with a GYEVI motif that is mistargeted to the cell surface would remain there; this may be detrimental to the cell and therefore unfavorable evolutionarily. Another pos- Figure 10 . Indirect immunofluorescence steady-state localization of wild-type human CD63, GYEVI, and CD63-TGN38 constructs in stable lines of transfected NRK cells treated with chloroquine. Stably transfected NRK cell lines expressing either the GYEVI construct (A and B), CD63-TGN38 (C and D), or wild-type CD63 (E and F) were incubated for 2 h in the presence of both 3 M CdCl 2 and 100 M chloroquine before fixation. The cells were then double labeled, for indirect immunofluorescence localization, with a mouse mAb to human CD63 (A, C, and E) and a rabbit polyclonal antibody to the lumenal domain of rat TGN38 (B, D, and F). Structures positive for TGN38, but which do not label with the anti-CD63 antibody, are indicated by single-headed arrows. Structures that label with both the TGN38 antibody and the CD63 antibody are indicated by the double-headed arrows. Bar, 10 m.
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Vol. 13, March 2002sible explanation relates to the possible functions of CD63 at the cell surface, including involvement in cell adhesion (Vischer and Wagner, 1993; Hamamoto et al., 1994) and integrinmediated cell migration (Berditchevski and Odintsova, 1999) . Alterations in the amount of CD63 expressed in melanomas have been implicated in metastatic progression of the tumor, and this may reflect altered cell surface expression (Hara et al., 1994; Radford et al., 1997) , suggesting that the amount of CD63 on the cell surface may be capable of modulation. Because the distribution of the wild-type molecule is clearly dependent on interactions of the carboxyterminal cytosolic tail with more than one adaptor protein, regulation of such interactions would provide a means of varying the cell surface concentration and may be a fruitful subject of future investigation.
